Chronic pain management with rechargeable spinal
cord stimulators
In March and April of 2005, the Food and Drug Administration
gave its approval to two implantable devices that
patients can recharge on their own:
|
In addition, Boston
Scientific Corp. has an FDA-approved rechargeable
device called the Precision™ Spinal
Cord Stimulation System, which was made available
in the U.S.
Neurostimulation systems for pain management
|
-
Eon™ Neurostimulation System
Advanced Neuromodulation Systems’ Eon
device consists of leads (placed above the spinal
cord), a small generator/receiver (implanted
under the skin) and a programmer/transmitter
that also allows for remote control of stimulation
intensity. The battery life is currently estimated
at seven years, and the company plans
to submit data to the FDA in order to receive
support for an even longer battery life claim.
-
RESTORE™ Rechargeable Neurostimulation
System
Medtronic’s
device, called the Restore Rechargeable Neurostimulation
System, uses a battery with an estimated nine-year total
life span. When batteries run low, patients
using the device will hear an alarm go off and
see an icon appear on the programmer screen. In
order to recharge, they will need to use a recharger
that they can carry in a pouch on their body. It
takes about six hours to fully recharge the batteries
and the activity should usually be repeated once
each month.
-
Precision™ Spinal Cord Stimulation
System
Boston
Scientific’s Precision device consists of
leads and a generator that are implanted under
the skin and external parts (a remote control,
a charger and charging station) and its battery
life is estimated at five years. Recharging
takes a few hours and requires placing a portable
cordless recharger over the implant.
Pain relief trial
Before a patient commits
to a full system implantation, he or she will likely
have a stimulation trial in order to make sure that
spinal cord stimulation is likely to provide pain
relief for the patient. During such a trial, one
or several leads are implanted into the patient’s lower back for a short period
of time (usually several days) and are connected
to a temporary spinal cord stimulator. A trial
stimulator contains up to several stimulation programs
with the goal of providing optimal treatment for
the patient, customized to fit the patient’s
needs. If trial therapy provides sufficient
relief from pain, which may differ in individual
cases, the patient can be scheduled for another procedure
and receive permanent implants. In the case
of an unsuccessful trial when stimulation does not
bring desired effects, the trial system will be removed
and other treatment options analyzed.
Cost of rechargeable spinal cord stimulators
The initial cost of the rechargeable stimulators
is expected to be more than that of non-rechargeable
devices. While non-rechargeable stimulators
sell for about $15,000, the cost of new stimulators
is expected to amount to approximately $17,000. Both
Medicare and private insurance are expected to cover
the rechargeable devices mentioned in this article,
if appropriate indications are met.
Spinal cord stimulator side effects
Implantable
rechargeable spine stimulators with prolonged battery
life are a new option for treatment of neuropathic
chronic pain. The primary benefit of this technology
is that it is expected to decrease the number of
replacement surgeries needed. It is important to
remember, however, that it is not designed to improve
the efficacy of a spinal cord stimulator in terms
of managing a patient’s
pain.
While the risk of complications with implantable
spinal cord stimulators is low relative to many other
more invasive surgical procedures, and the stimulation
systems may be removed at any time, it is important
for patients to talk to their doctors abut any possible
risk factors and side effects that may include:
-
Bleeding
-
Allergic reactions
-
Paralysis
-
Numbness
-
Consistent pain around the implant area
-
Battery failure or leakage
-
Post surgical soreness
-
Tolerance to stimulation secondary to scar formation
over time.
By: Thomas
M. Wascher, MD, FACS
September 23, 2005
|
|